

1 Title

2 Co-development of gut microbial metabolism and visual neural circuitry in human infants
3

4 Authors

5 Kevin S. Bonham
6 Emma T. Margolis
7 Guilherme Fatur Bottino
8 Fadheela Patel
9 Shelley McCann
10 Michal R. Zieff
11 Kirsty A. Donald
12 Laurel J. Gabard-Durnam*
13 Vanja Klepac-Ceraj*
14

15 ORCID numbers:

16 Kevin S. Bonham:	0000-0003-3200-7533
17 Guilherme Fatur Bottino:	0000-0003-1953-1576
18 Emma T. Margolis:	0000-0002-2036-8078
19 Fadheela Patel:	0000-0001-5177-7416
20 Michal Zieff:	0000-0001-9352-9947
21 Shelley McCann:	0000-0002-9753-7968
22 Kirsten A. Donald:	0000-0002-0276-9660
23 Laurel J. Gabard-Durnam	0000-0002-4564-8068
24 Vanja Klepac-Ceraj:	0000-0001-5387-5706

25
26

27 **Running title:** Infant gut microbiome associates with visual neurodevelopment

28

29 Abstract

30 Infancy is a time of rapid brain development supporting foundational sensory learning. The gut
31 microbiome, also undergoing extensive developmental changes in early life, may influence brain
32 development through metabolism of neuroactive compounds. Here, we show across the first 18
33 months of life that microbial genes encoding enzymes that produce and degrade neuroactive
34 compounds, including neurotransmitters GABA and glutamate, the amino acid tryptophan, and
35 short-chain fatty acids including acetate and butyrate, are associated with visual
36 neurodevelopmental learning, measured by the visual-evoked potential (VEP). Microbial gene
37 sets from stool collected around 4 months of age were strongly associated with VEP features
38 measured from 9 to 14 months of age and showed more associations than concurrently
39 measured gene sets, suggesting microbial metabolism in early life may have long term effects
40 on neural plasticity and development.

41 Introduction

42 The gut microbiome in early life has potential long-term implications for brain and body health.
43 One important way this influence can occur is through interactions with the central nervous
44 system as a “microbial-gut-brain-axis” (Rhee, Pothoulakis, and Mayer 2009; Collins, Surette,
45 and Bercik 2012). The metabolic potential of the microorganisms that inhabit the gut vastly
46 exceeds that of human cells alone, with microbial genes outnumbering host genes by a
47 hundredfold (Gilbert et al. 2018). In particular, gut microbes have the ability to metabolize and
48 synthesize many neuroactive compounds (Valles-Colomer et al. 2019). Extensive work in
49 preclinical models suggests that these neuroactive compounds can influence the brain through
50 both direct and indirect routes. For example, major neurotransmitters (e.g., glutamate, γ -
51 aminobutyric acid (GABA), serotonin, and dopamine) are readily synthesized and degraded by
52 intestinal microbes and can directly stimulate enteric nerve cells or enter circulation and pass
53 the blood-brain barrier to influence central nervous function (Janik et al. 2016; Ahmed et al.
54 2022). Glutamatergic/GABA-ergic signaling is critical for balancing the brain’s excitatory and
55 inhibitory neurotransmission levels, and bi-directional glutamatergic/GABA-ergic signaling
56 between the gut microbiome and brain is implicated in several physical and mental health
57 conditions (Filpa et al. 2016; Baj et al. 2019). Similarly, the gut and the microbiome are critical to
58 the regulation of metabolism for the neurotransmitters serotonin and dopamine, particularly
59 through the metabolism of dietary tryptophan (Agus, Planchais, and Sokol 2018). Moreover,
60 short-chain fatty acids (SCFAs) produced by the gut microbiome may impact the brain directly
61 by modulating neurotrophic factors, glial and microglial maturation, and neuroinflammation
62 (Dalile et al. 2019; Erny et al. 2021). Other indirect pathways for gut microbial influence on the
63 brain include vagus nerve stimulation, neuroendocrine modulation and immune system
64 regulation (Rhee, Pothoulakis, and Mayer 2009).

65
66 Rapidly growing literature connects the metabolic potential of the gut microbiome and brain
67 function in humans (reviewed in (Ahmed et al. 2022; Parker, Fonseca, and Carding 2019;
68 Aburto and Cryan 2024)), however, the overwhelming majority of this research is performed in
69 adults. Importantly, both the gut microbiome and the brain undergo dramatic and rapid
70 development over the first postnatal years (Yassour et al. 2016; Bonham et al. 2023; Lippé et al.
71 2007; Dean et al. 2014). However, very little is currently known about how gut-brain influences
72 emerge or change during this critical window for both systems (Ahrens et al. 2024; Meyer et al.
73 2022). Interrogating this early co-development in humans is therefore key to both understanding
74 adaptive gut-brain function and behavior and informing strategies to support it. The visual cortex
75 has been shown to be sensitive to gut microbiome modulations in adults (Canipe, Sioda, and
76 Cheatham 2021) and in rodents (Lupori et al. 2022), yet the visual cortex undergoes its most
77 rapid period of plasticity and maturation over infancy when the microbiome changes most
78 significantly (Deen et al. 2017; Ellis et al. 2021; Kiorpes 2015). Visual cortical maturation can be
79 robustly indexed via EEG with the visual-evoked potential (VEP) response to visual stimuli from
80 birth. The VEP is especially useful for indexing visual neurodevelopment as its morphology
81 includes amplitude deflections and latencies to those deflections that reflect maturation of
82 function and structure, respectively.


83

84 Here, we investigated the co-development of microbial gene functional potential - specifically
85 genes encoding enzymes that metabolize neuroactive compounds - and visual
86 neurodevelopment as indexed by the VEP in a longitudinal community sample of 185 infants
87 from Gugulethu in Cape Town, South Africa recruited as part of an ongoing prospective study,
88 called “Khula” (Zieff et al. 2024). Stool samples and EEG were collected at up to 3 visits in the
89 first 18 months of life. Shotgun metagenomic sequencing was used to obtain microbial gene
90 sequences from infant stool samples. To index visual cortical development, latencies and
91 amplitudes were extracted from each deflection component of the VEP (i.e., first negative-going
92 deflection, N1; first positive-going deflection, P1; and second negative-going deflection, N2),
93 producing six VEP features of interest. We evaluated the concurrent association between
94 microbial genes and VEP amplitudes and latencies and tested prospective influences of
95 microbial genes from early visits on VEP changes at later visits to reveal the temporal dynamics
96 of gut-brain co-development within individuals during this most critical window of plasticity.
97

98 Results

99 The brain and microbiome develop rapidly in the first months of life

100 To investigate the co-development of the gut microbiome and visual neurodevelopment, we
101 collected stool and measured VEP in a longitudinal cohort of 194 children in South Africa in the
102 first 18 months of life (Figure 1A, B, Table 1; visit 1, N = 119, age 3.6 ± 0.7 months, visit 2, N =
103 144, age 8.7 ± 1.4 months, visit 3, N = 130, age 14.2 ± 1.0 months). As expected for children at
104 this age (Koenig et al. 2011; Yassour et al. 2016; Bäckhed et al. 2015), the microbial
105 composition was developmentally dependent, with the first principle coordinate axis for both
106 taxonomic profiles (Figure 1C; variance explained = 15.1%; $R = -0.50$) and functional profiles
107 (Figure 1D; variance explained = 12.9%; $R = -0.57$) driven strongly by the age of the subject at
108 the time of collection. Similarly, both amplitude and latency VEP features were also strongly
109 correlated with age, such that latencies (especially P1 and N2) became shorter, while the P1
110 became less positive and the N1 and 2 components became more negative in amplitude as
111 infants got older (Figure 1E).
112



113

114 **Fig. 1: The gut microbiome and VEP both develop over the first 18 months of life.**

115 (A) Study design; participants (N=194) were seen up to 3 times over the first 18 months of life.

116 Metagenomes and EEG data were collected, generating microbial functional profiles (stool) and VEP

117 waveforms (EEG) used in subsequent analyses. (B) Longitudinal sampling of study participants; Density

118 plots (top) for stool and EEG collection show the ages represented in each visit. The scatter plot (bottom)

119 shows individual participant visits. Dotted lines connect separate visits for the same participant. When

120 stool and EEG data were collected for the same visit (purple) but not on the same day, dot represents the

121 median age of collection, and vertical bars in blue and red represent stool and EEG collections

122 respectively. (C) Principal coordinate analysis (PCoA) by multidimensional scaling (MDS) on Bray-Curtis

123 dissimilarity of taxonomic profiles; percent variance explained (fraction of positive eigenvalues) by each of

124 the first two axes are indicated on the x and y axes respectively. (D) PCoA of microbial functional profiles

125 (UniRef90s). (E) Average VEP waveforms at each visit.

126

127 Microbial genes with neuroactive potential are associated with visual 128 development

129 To test whether microbial metabolic potential was related to early life brain activity, we

130 performed feature set enrichment analysis (FSEA) using groups of potentially neuroactive

131 microbial genes and the VEP amplitude and latency features (Bonham et al. 2023; Valles-


132 Colomer et al. 2019). For each gene set that had at least 5 genes represented in a given

133 comparison group, logistic regression was performed using VEP features as predictors and the

134 presence or absence of each microbial gene in the metagenome as the response to determine

135 concurrent associations (see Methods). Z statistics for in-set genes were compared to all genes

136 using a permutation test to determine significance of the associations as described in
 137 (Subramanian et al. 2005). Of the 35 genesets assessed, 19 had sufficient representation to
 138 test, and of those, 18 were significantly associated with at least one EEG feature during at least
 139 one visit within the 18-month window after correcting for false discovery rate (Benjamini-
 140 Hochberg, $q < 0.2$; Figure 2, Table 2). Microbial genes involved in synthesis or degradation of
 141 molecules with neuroactive potential were associated with both VEP amplitudes or latencies at
 142 each visit, demonstrating widespread associations between early life gut microbiome and visual
 143 cortex neurodevelopment. The number of these associations increased over time (visit 1 had 6
 144 associations, visit 2 had 24, and visit 3 had 37), which could reflect the fact that *in utero*
 145 development is thought to occur in a sterile environment, providing less opportunity for microbial
 146 metabolism to influence visual cortex development in the first 3 months of life.



147
 148 **Fig. 2: Concurrent feature set enrichment analysis of microbial neuroactive genes and VEP for**
 149 **three visits.**

150 FSEA results for all genesets where at least one visit had a significant hit ($q < 0.2$) with at least one VEP
 151 latency (A) or amplitude (B). Dots indicate the Z-statistic from logistic regression for each gene in a gene
 152 set. Vertical bars indicate the median Z-statistic for the gene set as a whole. Y-axis position for each gene
 153 set indicates visit number. Visit 1 for inositol degradation and DOPAC synthesis were not tested, since
 154 there were fewer than 5 genes from those genesets present in the sample (See Methods).

156 Specifically, across the gene sets involved in neurotransmitter synthesis and degradation,
 157 glutamate synthesis showed robust associations with all VEP features, primarily at the 3rd visit
 158 (mean age 14.3 months), while glutamate degradation was weakly but significantly associated
 159 only with the amplitude of N2 at visit 3. GABA synthesis was also associated with the latency of
 160 the P1 peak at visit 1 (mean age 3.6 months). The regulation of this balance between glutamate
 161 and GABA (i.e., excitatory/inhibitory balance) is important for modulating neuroplasticity in the
 162 visual cortex during infancy (Fagiolini and Hensch 2000; Hensch et al. 1998), and suggests that
 163 microbial metabolism is related to the VEP as an index of this changing neuroplasticity. Gene

164 sets involved in tryptophan metabolism, which is linked to the metabolism of the
165 neurotransmitter serotonin as well as other neuroactive molecules such as kynurenine (Agus,
166 Planchais, and Sokol 2018) was associated with VEP latencies of P1 at visit 1, N1 and P1 at
167 visit 2, and N2 at visit 3. The degradation of quinolinic acid, also downstream of tryptophan
168 metabolism, was negatively enriched in children with shorter P1 latency at visit 1 and smaller P1
169 amplitude at visit 3, while the synthesis of quinolinic acid was positively associated with the
170 amplitude of the N2 peak at visit 1. Serotonin is a key regulator of other neurotransmitters, while
171 quinolinic acid is part of the kynurenine pathway and is a neurotoxin that can cause neuronal
172 dysfunction, but may also play a role in glutamate uptake in the brain (Lugo-Huitrón et al. 2013;
173 Tavares et al. 2000).


174

175 Amongst the short-chain fatty acid (SCFA) metabolizing gene sets tested, acetate synthesis
176 was strongly associated with all VEP features except N1 amplitude at visit 3, and also with N2
177 latency at visit 2. Propionate degradation was significantly associated with VEP latencies at
178 every visit over the 18-month window (N1 at visits 1 and 2, and both P1 and N2 at visit 3), as
179 well as with the amplitude of N1 at visit 3, while propionate synthesis was negatively associated
180 with N1 latency at visit 1 and positively associated with N2 amplitude at visit 3. Butyrate
181 synthesis is also associated with P1 and N2 latencies at visit 2, and with their amplitudes at visit
182 3. SCFAs play important roles in immune regulation, including neuroinflammation. Propionate is
183 widely regarded as neuroprotective, having indirect effects on the CNS by regulating
184 inflammatory responses and stimulating the release of GLP-1 from neuroendocrine cells in the
185 gut epithelium, while circulating butyrate increases myelination (Chen et al. 2019). Finally,
186 within the remaining gene sets tested, we observed robust associations in particular between
187 menaquinone (Vitamin K2) gene sets and the VEP features over this infancy window. This is
188 reassuring as vitamin K2 specifically is posited to promote healthy vision both outside of the
189 brain through effects on the retina and within the brain where it can protect neural circuits from
190 oxidative stress (Li et al. 2003). Notably, across significant gene set associations with VEP
191 features, the P1 and N2 component amplitudes and latencies were consistently the most
192 sensitive to these microbial gene sets. Both P1 and N2 components are known to show the
193 most dramatic changes with development during the first year of life and may best reflect
194 underlying visual learning and plasticity at this stage.

195 Microbial metabolic potential predicts future brain development in infancy

196 Given that differences in metabolic potential of the early life microbiome may exert their effects
197 over time, we sought to determine whether microbial genes at early time points were associated
198 with subsequent VEP development. To investigate this, we performed FSEA on stool samples
199 collected at visit 1 with VEP measured at visit 2 (age at stool collection = 3.6 ± 0.8 months, age
200 at VEP = 8.6 ± 1.5 months) or visit 3 (age at stool collection = 3.7 ± 0.7 months, age at VEP =
201 14.1 ± 1.1 months), as well as visit 2 stool samples with visit 3 VEP (age at stool collection = 8.9
202 ± 1.5 months, age at VEP = 14.3 ± 1.0 months) (Figure 3A). All gene sets except DOPAC
203 synthesis that had a significant hit with concurrently measured VEP were also significantly
204 associated with at least one future VEP feature (Figure 3B, Tables 2-5). Notably, the quantity of
205 those associations increased substantially for all longitudinal comparisons compared to
206 concurrent ones. For example, only 6 microbial gene sets were associated with visit 1 VEP, and

207 each of those was only associated with a single concurrently measured VEP feature. By
 208 contrast, 13 visit 1 gene sets were associated with visit 2 VEP features, and 11 were associated
 209 with visit 3 VEP features, the majority (9/13 for visit 2, 8/11 for visit 3) were associated with at
 210 least 2 VEP features, and nearly half (6/13 for visit 2, 5/11 for visit 3) were associated with more
 211 than 2.
 212



213 **Fig. 3: Gut microbial genes predict future VEP latencies and amplitudes**
 214 (A) Age distributions for stool samples (left) and VEP (right) for each longitudinal comparison (same
 215 individual) tested, V1 stool Z → V2 VEP, V1 stool → V3 VEP, and V2 stool → V3 VEP. As in Figure 2, (B) and
 216 (C) show FSEA results for all genesets where at least one visit had a significant hit ($q < 0.2$) with at least
 217 one VEP latency or amplitude respectively. Dots indicate the Z-statistic from logistic regression for each
 218 gene in a gene set. Vertical bars indicate the median Z-statistic for the gene set as a whole. The Y-axis
 219 position for each gene set indicates longitudinal comparison. V1 → V2 and V1 → 3 for inositol
 220 degradation and DOPAC synthesis were not tested, since there were fewer than 5 genes from those
 221 genesets present in the sample (See Methods).
 222
 223

224 **Table 2: Longitudinal FSEA, visit 1 stool -> visit 2 VEP**
 225

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	amp	P1	-0.3987298838	0.08078918919
		N2	0.3661036051	0.1129448276
Glutamate synthesis	latency	N1	-0.2829156583	0.04452
		P1	0.2625066112	0.08078918919
	amp	P1	0.2316538042	0.1023130435
Glutamate degradation	latency	P1	0.3369665011	0.1598153846
		N2	0.3252682367	0.1800808989
	amp	P1	0.3256631998	0.1760093023
Tryptophan synthesis	latency	N1	-0.2211303459	0.02725714286
		P1	0.1671470069	0.08078918919
		N2	0.1900183195	0.04845714286
	amp	N2	-0.1630723325	0.1023130435
Quinolinic acid synthesis	amp	N1	-0.2735268422	0.1609156627
Quinolinic acid degradation	latency	P1	0.1979735587	0.1023130435
		N2	0.1950682309	0.1118888889
Acetate synthesis	latency	N1	-0.2190895918	0.02935384615
		P1	0.1926523891	0.06115384615
		N2	0.2157444594	0.0318
	amp	P1	0.1860132394	0.0742
		N2	-0.1960332174	0.05492727273
Butyrate synthesis	amp	N1	-0.3193476197	0.1698494118
Isovaleric acid synthesis	latency	N1	0.2711007176	0.1223076923
	amp	N1	0.2412188311	0.1800808989
		P1	-0.2409522895	0.1609156627
Menaquinone synthesis	latency	N1	-0.1393490274	0.1598153846
Inositol synthesis	amp	N1	-0.4295268274	0.1804304348
	latency	N1	-0.4219126859	0.1834357895
p-Cresol synthesis	amp	N1	-0.3665789266	0.1825935484
		P1	0.452086746	0.1014571429
		N2	-0.5164507055	0.04452
17-beta-Estradiol degradation	latency	N2	0.3550449716	0.1800808989

226
227
228

229 **Table 3: Longitudinal FSEA, visit 1 stool -> visit 3 VEP**
 230

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	latency	P1	0.4343386934	0.04452
	amp	P1	0.4099001639	0.0742
		N2	-0.5065759161	0.02544
Glutamate synthesis	latency	N1	-0.3035011084	0.02935384615
	amp	N1	-0.2344054782	0.1118888889
Tryptophan synthesis	latency	N1	-0.1875306139	0.04452
	amp	P1	-0.2176124281	0.0159
Quinolinic acid degradation	latency	P1	-0.1862809727	0.109392
		N2	-0.2624478514	0.1834357895
	amp	P1	-0.1689430121	0.1609156627
Acetate synthesis	latency	N1	-0.1728769986	0.08078918919
Propionate synthesis	amp	P1	0.3586598762	0.08078918919
Propionate degradation	latency	N1	-0.5097549612	0.109392
		P1	0.5345516637	0.08806153846
	amp	P1	0.738806805	0
		N2	-0.6669122013	0.02725714286
Butyrate synthesis	latency	N1	0.3373261944	0.1223076923
		N2	-0.3232764867	0.1498520548
	amp	P1	0.368868764	0.1014571429
Menaquinone synthesis	latency	P1	0.1582676302	0.08703157895
	amp	N1	-0.1417486481	0.1397408451
		P1	0.1488038682	0.1131864407
		N2	-0.1567020165	0.1023130435
Inositol synthesis	amp	N2	-0.4538038427	0.1210451613
ClpB	latency	N1	-0.2835050435	0.1804304348
	amp	P1	-0.3284206328	0.1129448276
		N2	0.3585858703	0.08001290323

232 **Table 4: Longitudinal FSEA, visit 2 stool -> visit 3 VEP**
 233

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	latency	N1	-0.3762158971	0.107325
Glutamate synthesis	latency	N1	-0.1676219701	0.1609156627
		P1	0.2979689116	0.0159
Glutamate degradation	amp	P1	0.23424529	0.03816
	latency	P1	0.3174180129	0.14045
Tryptophan synthesis	amp	N2	0.2829464416	0.187555102
		N1	-0.1554890366	0.06083478261
Quinolinic acid synthesis	latency	P1	0.1865391121	0.02935384615
		N1	-0.3186382801	0.061056
Acetate synthesis	amp	P1	0.333137823	0.043725
		P1	0.2577611214	0.1391826087
		N1	-0.1673242602	0.061056
Propionate synthesis	latency	P1	0.2574696731	0
		N2	-0.1373776916	0.1529837838
		P1	0.1469554921	0.1210451613
Propionate degradation	amp	P1	0.2994151994	0.1262363636
Butyrate synthesis	latency	N1	-0.5503973578	0.0742
		N2	0.4492537427	0.1609156627
	amp	P1	0.5088146404	0.111888889
		N2	-0.4229989983	0.187555102
Isovaleric acid synthesis	latency	N1	-0.3316428446	0.08078918919
		P1	0.3335618515	0.0742
		N2	-0.2908124776	0.1223076923
Menaquinone synthesis	amp	N2	0.3066681625	0.111888889
		P1	0.2316852688	0.1556526316
		P1	0.2469367892	0.1129448276
		N1	0.1528795641	0.1210451613
Inositol degradation	latency	N1	-0.1644331641	0.107325
		P1	0.2014568364	0.02935384615
		N2	-0.1634034966	0.1121672727
Inositol degradation	latency	N1	-0.6381259915	0.02935384615
		P1	0.5323381792	0.1014571429

	amp	P1	0.6413929993	0.02935384615
p-Cresol synthesis	latency	P1	0.3118799423	0.1397408451
		N2	-0.3152864697	0.1391826087
	amp	N1	-0.3039764673	0.1658142857
S-Adenosylmethionine synthesis	amp	N1	-0.2228894468	0.1556526316
		P1	0.2295724682	0.1347940299
17-beta-Estradiol degradation	amp	P1	0.2818613888	0.187555102
ClpB	latency	P1	0.2687857561	0.1804304348

234 Neurotransmitters GABA and glutamate, tryptophan metabolism (tryptophan and quinolinic acid)
235 and SCFAs including menaquinone and acetate were all significantly associated with multiple
236 VEP features across multiple longitudinal comparisons.

237 Discussion

238 The past decade has seen a remarkable growth in our understanding of the relationships
239 between the gut microbiome and the brain. However, a great deal of that investigation has
240 focused on neuropsychiatric disorders or atypical development, and animal models of those
241 disorders (e.g., autism spectrum disorder, depression/anxiety) have an unknown relationship to
242 the human disorders that they represent, limiting their explanatory potential. A research program
243 that investigates typical development using non-invasive measurements in humans, that is
244 accurate and reproducible and shows variation in the first year of life, and that is directly
245 measurable in rodent models is sorely needed. The relationship between gut microbial
246 metabolism and VEP development offers just such a paradigm.

247
248 Here, we have shown a robust, prospective relationship between microbial genes involved in
249 the metabolism of neuroactive compounds and the development of visual response in the brain
250 as measured by EEG. It is particularly encouraging that the microbial metabolism earlier in life is
251 more strongly associated with future measures of VEP than those collected concurrently. While
252 not dispositive, this would be the predicted outcome if microbial genes are causally influencing
253 brain development. It is also encouraging that the gene sets most associated with VEP
254 development are for the metabolism of molecules with known links to developmental
255 neuroplasticity and development of the visual cortex (Fagiolini and Hensch 2000; Hensch et al.
256 1998; Takesian et al. 2018).

257
258 Interestingly, the sign of several associations changes from one comparison to another. For
259 example, acetate synthesis, tryptophan synthesis, and quinolinic acid degradation are all
260 positively associated with N2 latency when comparing visit 1 stool to visit 2 VEP, but negatively
261 associated when comparing visit 2 stool to visit 3 VEP. The sign of tryptophan synthesis
262 associations is particularly unstable; it is positively associated with P1 latency when comparing
263 visit 1 or visit 2 stool to the following visit VEP, but negatively associated when comparing visit 1
264 stool to visit 3 VEP, is negatively associated with P1 amplitude and N2 amplitude in one

265 comparison but positively associated in another. These results suggest that the impact of
266 microbial metabolism on brain development may be context dependent.

267
268 One limitation of this study is the fact that we are only able to observe the genomic composition
269 of the microbiome, rather than the concentration of metabolites themselves. This prevents us
270 from determining the concentration of these molecules in the gastrointestinal tract, blood, and
271 brain, as the abundance of these genes does provide information about their activity, their
272 interactions with other metabolic pathways (including those of the host), or absorption by colonic
273 epithelial cells. Additionally, the relationship between gene abundance and molecule
274 concentration may be counterintuitive. For example, genes for breaking down a molecule may
275 be prevalent if that molecule is at high concentrations, or the molecules may be rapidly
276 degraded by other members of the community the moment they are produced. The balance of
277 degradation and synthesis occurs both at the individual organism level and at the community
278 level. This may also explain the somewhat puzzling results where some gene set / VEP feature
279 associations change from positive to negative association (or vice versa) when comparing
280 different timepoints. It may be that the relationship between metabolite and brain development
281 remains the same, while the relationship between molecules and microbial selection changes at
282 different stages of life. Addressing these limitations in humans is challenging, even if looking at
283 stool metabolites, since overall exposure throughout the gastrointestinal tract is not necessarily
284 reflected in the final concentration of those molecules in stool. Therefore, metabolites from
285 blood plasma could provide more accurate systemic concentrations of molecules, but
286 challenges remain on how to interpret them (Deng et al. 2023; Dekkers et al. 2022).

287
288 Given that the VEP is evolutionarily conserved in mammals and can be accurately measured
289 during rodent development, the hypotheses generated in humans in this study are readily
290 testable using *in vivo* models. Germ free or defined-microbiome animals (Wymore Brand et al.
291 2015; Kennedy, King, and Baldrige 2018) may be supplemented with specific molecules such
292 as SCFAs, or colonized with microbial species lacking or providing specific metabolic pathways,
293 and molecule concentrations in tissues from the gut to the brain can be directly assessed.
294 Uncovering relationships between microbial metabolism and specific molecules may also
295 generate hypotheses that can be confirmed in human data. This study provides a foundation for
296 deep investigation of the relationships between the gut microbiome and brain development.

297
298

299 Materials and methods

300 Cohort, ethics, etc

301 Participants and Study Design

302 Infants were recruited from local community clinics in Gugulethu, an informal settlement, in Cape
303 Town, South Africa as part of an ongoing longitudinal study (most of the enrollment happened
304 prenatally with 39% of infants enrolled shortly after birth (Zieff et al. 2024)). The first language for
305 the majority of residents in this area is Xhosa. Study procedures were offered in English or Xhosa
306 depending on the language preference of the mother. This study was approved by the relevant

307 university Health Research Ethics Committees (University of Cape Town study number:
308 666/2021). Informed consent was collected from mothers on behalf of themselves and their infants.
309 Demographic information including maternal place of birth, primary spoken language, maternal
310 age at enrollment, maternal educational attainment, and maternal income were collected at
311 enrollment (see Table 1).

312
313 Families were invited to participate in three in-lab study visits over their infant's first year and a
314 half of life. At the first in-lab study visit (hereafter Visit 1), occurring when infants were between
315 approximately 2 months and 6 months of age, the following data were collected: the infants' age
316 (in months), sex, infant electroencephalography (EEG), and infant stool samples.

317
318 At the second study visit (hereafter Visit 2), occurring when infants were between approximately
319 6 months and 12 months of age (age in months: $M=8.60$, $SD=1.48$, $range=5.41-12.00$) and at
320 the third study visit (hereafter Visit 3), occurring when infants were between approximately 12
321 months and 17 months of age (age in months: $M=14.10$, $SD=1.04$, $range=12.10-17.00$), infant
322 EEG and stool samples were collected again. At visits in which infants were unable to complete
323 both EEG and stool samples on the same day, EEG and stool samples were collected on
324 different days. For concurrent time point analyses, infants with EEG and stool collected more
325 than two months apart were excluded. Not all infants had EEG and microbiome data collected at
326 all three timepoints or contributed usable data at all three timepoints.

327
328 All enrolled infants received a comprehensive medical exam at each visit, which included
329 assessments of eye-related conditions. Several infants ($n=3$) were identified as having eye-
330 related anomalies during the medical exam, and they were excluded from any further analyses.

331 EEG Processing

332 EEG Data Acquisition

333 Electroencephalography (EEG) data were acquired from infants while they were seated in their
334 caregiver's lap in a dimly-lit, quiet room using a 128-channel high density HydroCel Geodesic
335 Sensor Net (EGI, Eugene, OR), amplified with a NetAmps 400 high-input amplifier, and
336 recorded via an Electrical Geodesics, Inc. (EGI, Eugene, OR) system with a 1000 Hz sampling
337 rate. EEG data were online referenced to the vertex (channel Cz) through the EGI Netstation
338 software. Impedances were kept below 100K Ω in accordance with the impedance capabilities of
339 the high-impedance amplifiers. Geodesic Sensor Nets with modified tall pedestals designed for
340 improving inclusion of infants with thick/curly/tall hair were used as needed across participants
341 (Mlandu et al., 2024). Shea moisture leave-in castor oil conditioner was applied to hair across
342 the scalp prior to net placement to improve both impedances and participant comfort (Mlandu et
343 al., 2024). This leave-in conditioner contains insulating ingredients so there is no risk of
344 electrical bridging and has not been found to disrupt the EEG signal during testing (unpublished
345 data). Conditioning hair in this way allows for nets to lay closer to the scalp for curly/coily hair
346 types and makes for far more comfortable net removal at the end of testing.

347
348 The Visual-Evoked Potential (VEP) task was presented using Eprime 3.0 software (Psychology
349 Software Tools, Pittsburgh, PA) on a Lenovo desktop computer with an external monitor 19.5
350 inches on the diagonal facing the infant (with monitor approximately 65 cm away from the
351 infant). A standard phase-reversal VEP was induced with a black and white checkerboard (1cm
352 x 1 cm squares within the board) stimulus that alternated presentation (black squares became
353 white, white squares became black) every 500 milliseconds for a total of 100 trials. Participant
354 looking was monitored by video and by an assistant throughout data collection. If the participant
355 looked away during the VEP task, the task was rerun.

356

357 **EEG Data Pre-Processing**

358 VEP data were exported from native Netstation .mff format to .raw format and then pre-
359 processed using the HAPPE+ER pipeline within the HAPPE v3.3 software, an automated open-
360 source EEG processing software validated for infant data (Monachino et al. 2022). A subset of
361 the 128 channels were selected for pre-processing that excluded the rim electrodes as these
362 are typically artifact-laden. The HAPPE pre-processing pipeline was run with user-selected
363 specifications.

364

365 Pre-processed VEP data were considered usable and moved forward to VEP extraction if
366 HAPPE pre-processing ran successfully, at least 15 trials were retained following bad trial
367 rejection, and at least one good channel was kept within the visual ROI. Note that channels
368 marked bad during pre-processing had their data interpolated as part of standard pre-
369 processing pipelines for ERPs (Monachino et al. 2022). Interpolated channels were included in
370 analyses here as is typically done in developmental samples and given the low overall rates of
371 interpolation present (e.g., all groups at all visits had an average of between 4 to 5 of 5 possible
372 good channels in the region of interest retained).

373

374 **Visual-Evoked Potentials (VEPs)**

375 VEP waveforms were extracted and quantified using the HAPPE+ER v3.3 GenerateERPs script
376 (Monachino et al. 2022). Electrodes in the occipital region were selected as a region of interest
377 (i.e., E70, E71, E75, E76, E83). The VEP waveform has three main components to be
378 quantified: a negative N1 peak, a positive P1 peak, and a negative N2 peak. Due to normative
379 maturation of the waveforms as infants age, one set of user-specified windows for calculating
380 component features was used for Visit 1 and 2 and another was used for Visit 3. For Visits 1
381 and 2, the window for calculating features for the N1 component was 40-100 ms, 75-175 ms for
382 the P1 component, and 100-325 ms for the N2 component. For Visit 3, the window for
383 calculating features for the N1 component was 35-80 ms, 75-130 ms for the P1 component, and
384 100-275 ms for the N2 component.

385

386 To correct for the potential influence of earlier components on later components, corrected
387 amplitudes and latencies were calculated and used in all analyses. Specifically, the P1
388 amplitude was corrected for the N1 amplitude (corrected P1 amplitude = P1 - N1 amplitude); the
389 P1 latency was corrected for the N1 latency (corrected P1 latency = P1 - N1 latency); the N2
390 amplitude was corrected for the P1 amplitude (corrected N2 amplitude = N2 - P1 amplitude),
391 and the N2 latency was corrected for the P1 latency (corrected N2 latency = N2 - P1 latency).

392

393 All VEPs were visually inspected to ensure that the automatically extracted values were correct
394 and were adjusted if observable peaks occurred outside the automated window bounds.
395 Participants were considered to have failed this visual inspection and were subsequently
396 removed from the data set if their VEP did not produce three discernible peaks. VEP waveforms
397 of included participants by timepoint are included in Figure 1E. XX infants provided usable VEP
398 data at Visit 1, XX infants provided usable VEP data at Visit 2, and XX infants provided usable
399 VEP data at Visit 3. There were no differences in EEG quality (i.e., number of trials collected,
400 number/percent of trials retained, number/percent of channels retained overall, number/percent
401 of channels retained in ROI) by time point (all $p > .05$).

402 **Biospecimens and sequencing**

403 **Sample Collection**

404 Stool samples were collected in the clinic by the research assistant directly from the diaper and
405 transferred to the Zymo DNA/RNA Shield™ Fecal collection Tube (#R1101, Zymo Research
406 Corp., Irvine, USA) and immediately frozen at -80 °C. Stool samples were not collected if the
407 subject had taken antibiotics within the two weeks prior to sampling.

408

409 **DNA Extraction**

410 DNA extraction was performed at Medical Microbiology, University of Cape Town, South Africa
411 from stool samples collected in DNA/RNA Shield™ Fecal collection tube using the Zymo
412 Research Fecal DNA MiniPrep kit (# D4003, Zymo Research Corp., Irvine, USA) following
413 manufacturer's protocol. To assess the extraction process's quality, ZymoBIOMICS® Microbial
414 Community Standards (#D6300 and #D6310, Zymo Research Corp., Irvine, USA) were
415 incorporated and subjected to the identical process as the stool samples. The DNA yield and
416 purity were determined using the NanoDrop® ND -1000 (Nanodrop Technologies Inc.
417 Wilmington, USA).

418

419 **Sequencing**

420 Shotgun metagenomic sequencing was performed on all samples at the Integrated Microbiome
421 Research Resource (IMR, Dalhousie University, NS, Canada). A pooled library (max 96
422 samples per run) was prepared using the Illumina Nextera Flex Kit for MiSeq and NextSeq from
423 1 ng of each sample. Samples were then pooled onto a plate and sequenced on the Illumina
424 NextSeq 2000 platform using 150+150 bp paired-end P3 cells, generating 24M million raw
425 reads and 3.6 Gb of sequence per sample.

426 **Statistics / computational analysis**

427 **Metagenome processing**

428 Raw metagenomic sequence reads were processed using tools from the bioBakery as
429 previously described (Bonham et al. 2023; Beghini et al. 2021). Briefly, KneadData v0.10.0 was
430 used with default parameters to trim low-quality reads and remove human sequences (using
431 reference database hg37). Next, MetaPhlAn v3.1.0 (using database
432 mpa_v31_CHOCOPhAn_201901) was used with default parameters to map microbial marker
433 genes to generate taxonomic profiles. Taxonomic profiles and raw reads were passed to
434 HUMAnN v3.7 to generate stratified functional profiles.

435

436 **Microbial community analysis**

437 Principal coordinates analysis was performed in the julia programming language (Bezanson et
438 al. 2012) using the Microbiome.jl package (Bonham et al. 2021). Bray-Curtis dissimilarity
439 (Distances.jl) was calculated across all pairs of samples, filtering for species-level classification.
440 Classical multidimensional scaling was performed on the dissimilarity matrix
441 (MultivariateStats.jl), and axes with negative eigenvalues were discarded.

442

443 **Feature Set Enrichment Analysis (FSEA)**

444 Potentially neuroactive genesets were extracted from Supplementary Dataset 1 from (Valles-
445 Colomer et al. 2019). Gut-brain modules provide Kegg Orthologue IDs (KOs), which were
446 mapped to UniRef90 IDs using the utility mapping file provided with HUMAnN v3.1. For each

447 stool / VEP pair, logistic regression (LR) was performed linking the presence of absence of that
448 UniRef in a sample with each VEP feature (N1, P1, and N2 latencies and amplitudes),
449 controlling for the age at which the stool sample was collected, the number of retained VEP
450 trials, and the difference in age between the stool collection and VEP measurement. For
451 concurrently collected stool and VEP comparisons (Figure 2), subjects whose stool collection
452 and VEP measurements were more than 2 months apart were excluded.

453

454 (1) UniRef ~ vep + age_months + n_trials + age_diff

455

456 FSEA was performed on each geneset that had at least 5 members in each comparison group
457 according to the procedure set out in Subramanian *et. al.* (2005)(Subramanian et al. 2005).

458 Briefly, enrichment scores (ES) are calculated based on the rank-order of z-statistics from the
459 LR for each UniRef. A permutation test was then performed where the ES for 5000 random
460 samples of ranks of the same length as the gene set are calculated, and the pseudo-p value is
461 the number fraction of permutations where the permutation ES has a greater absolute value
462 than the true ES.

463

464 Benjamini-Hochberg FDR correction was performed separately on all concurrently tested
465 geneset / VEP feature combinations, and all longitudinal geneset / VEP feature combinations.
466 Corrected p-values (q values) less than 0.2 were considered statistically significant.

467 References

- 468 Aburto, María R., and John F. Cryan. 2024. "Gastrointestinal and Brain Barriers: Unlocking
469 Gates of Communication across the Microbiota–Gut–Brain Axis." *Nature Reviews*
470 *Gastroenterology & Hepatology* 21 (4): 222–47. [https://doi.org/10.1038/s41575-023-](https://doi.org/10.1038/s41575-023-00890-0)
471 [00890-0](https://doi.org/10.1038/s41575-023-00890-0).
- 472 Agus, Allison, Julien Planchais, and Harry Sokol. 2018. "Gut Microbiota Regulation of
473 Tryptophan Metabolism in Health and Disease." *Cell Host & Microbe* 23 (6): 716–24.
474 <https://doi.org/10.1016/j.chom.2018.05.003>.
- 475 Ahmed, Hany, Quentin Leyrolle, Ville Koistinen, Olli Kärkkäinen, Sophie Layé, Nathalie
476 Delzenne, and Kati Hanhineva. 2022. "Microbiota-Derived Metabolites as Drivers of
477 Gut–Brain Communication." *Gut Microbes* 14 (1): 2102878.
478 <https://doi.org/10.1080/19490976.2022.2102878>.
- 479 Ahrens, Angelica P., Tuulia Hyötyläinen, Joseph R. Petrone, Kajsa Igelström, Christian D.
480 George, Timothy J. Garrett, Matej Orešič, Eric W. Triplett, and Johnny Ludvigsson.
481 2024. "Infant Microbes and Metabolites Point to Childhood Neurodevelopmental
482 Disorders." *Cell* 187 (8): 1853-1873.e15. <https://doi.org/10.1016/j.cell.2024.02.035>.
- 483 Bäckhed, Fredrik, Josefine Roswall, Yangqing Peng, Qiang Feng, Huijue Jia, Petia Kovatcheva-
484 Datchary, Yin Li, et al. 2015. "Dynamics and Stabilization of the Human Gut Microbiome
485 during the First Year of Life." *Cell Host & Microbe* 17 (5): 690–703.
486 <https://doi.org/10.1016/j.chom.2015.04.004>.
- 487 Baj, Andreina, Elisabetta Moro, Michela Bistoletti, Viviana Orlandi, Francesca Crema, and
488 Cristina Giaroni. 2019. "Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis."
489 *International Journal of Molecular Sciences* 20 (6): 1482.
490 <https://doi.org/10.3390/ijms20061482>.
- 491 Beghini, Francesco, Lauren J McIver, Aitor Blanco-Míguez, Leonard Dubois, Francesco

- 492 Asnicar, Sagun Maharjan, Ana Mailyan, et al. 2021. "Integrating Taxonomic, Functional,
493 and Strain-Level Profiling of Diverse Microbial Communities with bioBakery 3." *Elife* 10
494 (May). <https://doi.org/10.7554/eLife.65088>.
- 495 Bezanson, Jeff, Stefan Karpinski, Viral B Shah, and Alan Edelman. 2012. "Julia: A Fast
496 Dynamic Language for Technical Computing," September.
497 <http://arxiv.org/abs/1209.5145>.
- 498 Bonham, Kevin, Guilherme Fatur Bottino, Shelley Hoeft McCann, Jennifer Beauchemin,
499 Elizabeth Weisse, Fatoumata Barry, Rosa Cano Lorente, et al. 2023. "Gut-Resident
500 Microorganisms and Their Genes Are Associated with Cognition and Neuroanatomy in
501 Children." *Science Advances* 9 (51): eadi0497. <https://doi.org/10.1126/sciadv.adi0497>.
- 502 Bonham, Kevin, Anelle Kayisire, Anika Luo, and Vanja Klepac-Ceraj. 2021. "Microbiome.Jl and
503 BiobakeryUtils.Jl - Julia Packages for Working with Microbial Community Data." *Journal*
504 *of Open Source Software* 6 (67): 3876. <https://doi.org/10.21105/joss.03876>.
- 505 Canipe, L. Grant, Michael Sioda, and Carol L. Cheatham. 2021. "Diversity of the Gut-
506 Microbiome Related to Cognitive Behavioral Outcomes in Healthy Older Adults."
507 *Archives of Gerontology and Geriatrics* 96 (September):104464.
508 <https://doi.org/10.1016/j.archger.2021.104464>.
- 509 Chen, Tong, Daisuke Noto, Yasunobu Hoshino, Miho Mizuno, and Sachiko Miyake. 2019.
510 "Butyrate Suppresses Demyelination and Enhances Remyelination." *Journal of*
511 *Neuroinflammation* 16 (1): 165. <https://doi.org/10.1186/s12974-019-1552-y>.
- 512 Collins, Stephen M., Michael Surette, and Premysl Bercik. 2012. "The Interplay between the
513 Intestinal Microbiota and the Brain." *Nature Reviews Microbiology* 10 (11): 735–42.
514 <https://doi.org/10.1038/nrmicro2876>.
- 515 Dalile, Boushra, Lukas Van Oudenhove, Bram Vervliet, and Kristin Verbeke. 2019. "The Role of
516 Short-Chain Fatty Acids in Microbiota-Gut-Brain Communication" 16 (8): 461–78.
517 <https://doi.org/10.1038/s41575-019-0157-3>.
- 518 Dean, Douglas C., Jonathan O'Muircheartaigh, Holly Dirks, Nicole Waskiewicz, Katie Lehman,
519 Lindsay Walker, Michelle Han, and Sean C. L. Deoni. 2014. "Modeling Healthy Male
520 White Matter and Myelin Development: 3 through 60 Months of Age." *NeuroImage* 84
521 (January):742–52. <https://doi.org/10.1016/j.neuroimage.2013.09.058>.
- 522 Deen, Ben, Hilary Richardson, Daniel D. Dilks, Atsushi Takahashi, Boris Keil, Lawrence L.
523 Wald, Nancy Kanwisher, and Rebecca Saxe. 2017. "Organization of High-Level Visual
524 Cortex in Human Infants." *Nature Communications* 8 (1): 13995.
525 <https://doi.org/10.1038/ncomms13995>.
- 526 Dekkers, Koen F., Sergi Sayols-Baixeras, Gabriel Baldanzi, Christoph Nowak, Ulf Hammar,
527 Diem Nguyen, Georgios Varotsis, et al. 2022. "An Online Atlas of Human Plasma
528 Metabolite Signatures of Gut Microbiome Composition." *Nature Communications* 13 (1):
529 5370. <https://doi.org/10.1038/s41467-022-33050-0>.
- 530 Deng, Kui, Jin-jian Xu, Luqi Shen, Hui Zhao, Wanglong Gou, Fengzhe Xu, Yuanqing Fu, et al.
531 2023. "Comparison of Fecal and Blood Metabolome Reveals Inconsistent Associations
532 of the Gut Microbiota with Cardiometabolic Diseases." *Nature Communications* 14 (1):
533 571. <https://doi.org/10.1038/s41467-023-36256-y>.
- 534 Ellis, Cameron T., Tristan S. Yates, Lena J. Skalaban, Vikranth R. Bejjanki, Michael J. Arcaro,
535 and Nicholas B. Turk-Browne. 2021. "Retinotopic Organization of Visual Cortex in
536 Human Infants." *Neuron* 109 (16): 2616-2626.e6.
537 <https://doi.org/10.1016/j.neuron.2021.06.004>.
- 538 Erny, Daniel, Nikolaos Dokalis, Charlotte Mezö, Angela Castoldi, Omar Mossad, Ori
539 Staszewski, Maximilian Frosch, et al. 2021. "Microbiota-Derived Acetate Enables the
540 Metabolic Fitness of the Brain Innate Immune System during Health and Disease." *Cell*
541 *Metabolism* 33 (11): 2260-2276.e7. <https://doi.org/10.1016/j.cmet.2021.10.010>.
- 542 Fagiolini, M., and T. K. Hensch. 2000. "Inhibitory Threshold for Critical-Period Activation in

- 543 Primary Visual Cortex.” *Nature* 404 (6774): 183–86. <https://doi.org/10.1038/35004582>.
- 544 Filpa, Viviana, Elisabetta Moro, Marina Protasoni, Francesca Crema, Gianmario Frigo, and
545 Cristina Giaroni. 2016. “Role of Glutamatergic Neurotransmission in the Enteric Nervous
546 System and Brain-Gut Axis in Health and Disease.” *Neuropharmacology* 111
547 (December):14–33. <https://doi.org/10.1016/j.neuropharm.2016.08.024>.
- 548 Gilbert, Jack A., Martin J. Blaser, J. Gregory Caporaso, Janet K. Jansson, Susan V. Lynch, and
549 Rob Knight. 2018. “Current Understanding of the Human Microbiome.” *Nature Medicine*
550 24 (4): 392–400. <https://doi.org/10.1038/nm.4517>.
- 551 Hensch, Takao K., Michela Fagiolini, Nobuko Mataga, Michael P. Stryker, Steinunn
552 Baekkeskov, and Shera F. Kash. 1998. “Local GABA Circuit Control of Experience-
553 Dependent Plasticity in Developing Visual Cortex.” *Science* 282 (5393): 1504–8.
554 <https://doi.org/10.1126/science.282.5393.1504>.
- 555 Janik, Rafal, Lysie A. M. Thomason, Andrew M. Stanisiz, Paul Forsythe, John Bienenstock,
556 and Greg J. Stanisiz. 2016. “Magnetic Resonance Spectroscopy Reveals Oral
557 Lactobacillus Promotion of Increases in Brain GABA, N-Acetyl Aspartate and
558 Glutamate.” *NeuroImage* 125 (January):988–95.
559 <https://doi.org/10.1016/j.neuroimage.2015.11.018>.
- 560 Kennedy, Elizabeth A., Katherine Y. King, and Megan T. Baldrige. 2018. “Mouse Microbiota
561 Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying
562 Gut Bacteria.” *Frontiers in Physiology* 9.
563 <https://www.frontiersin.org/articles/10.3389/fphys.2018.01534>.
- 564 Kiorpes, Lynne. 2015. “Visual Development in Primates: Neural Mechanisms and Critical
565 Periods.” *Developmental Neurobiology* 75 (10): 1080–90.
566 <https://doi.org/10.1002/dneu.22276>.
- 567 Koenig, Jeremy E, Aymé Spor, Nicholas Scalfone, Ashwana D Fricker, Jesse Stombaugh, Rob
568 Knight, Lergus T Angenent, and Ruth E Ley. 2011. “Succession of Microbial Consortia in
569 the Developing Infant Gut Microbiome.” *Proceedings of the National Academy of
570 Sciences of the United States of America* 108 Suppl 1 (March):4578–85.
571 <https://doi.org/10.1073/pnas.1000081107>.
- 572 Li, Jianrong, Judith C. Lin, Hong Wang, James W. Peterson, Barbara C. Furie, Bruce Furie,
573 Sara L. Booth, Joseph J. Volpe, and Paul A. Rosenberg. 2003. “Novel Role of Vitamin K
574 in Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons.” *Journal of
575 Neuroscience* 23 (13): 5816–26. [https://doi.org/10.1523/JNEUROSCI.23-13-
576 05816.2003](https://doi.org/10.1523/JNEUROSCI.23-13-05816.2003).
- 577 Lippé, S, M-S Roy, C Perchet, and M Lassonde. 2007. “Electrophysiological Markers of
578 Visuocortical Development.” *Cerebral Cortex* 17 (1): 100–107.
579 <https://doi.org/10.1093/cercor/bhj130>.
- 580 Lugo-Huitrón, Rafael, Perla Ugalde Muñiz, Benjamin Pineda, José Pedraza-Chaverrí, Camilo
581 Ríos, and Verónica Pérez-de la Cruz. 2013. “Quinolinic Acid: An Endogenous
582 Neurotoxin with Multiple Targets.” *Oxidative Medicine and Cellular Longevity*
583 2013:104024. <https://doi.org/10.1155/2013/104024>.
- 584 Lupori, Leonardo, Sara Cornuti, Raffaele Mazziotti, Elisa Borghi, Emerenziana Ottaviano,
585 Michele Dei Cas, Giulia Sagona, Tommaso Pizzorusso, and Paola Tognini. 2022. “The
586 Gut Microbiota of Environmentally Enriched Mice Regulates Visual Cortical Plasticity.”
587 *Cell Reports* 38 (2): 110212. <https://doi.org/10.1016/j.celrep.2021.110212>.
- 588 Meyer, Katie, Anju Lulla, Kunal Debroy, James M. Shikany, Kristine Yaffe, Osorio Meirelles, and
589 Lenore J. Launer. 2022. “Association of the Gut Microbiota With Cognitive Function in
590 Midlife.” *JAMA Network Open* 5 (2): e2143941.
591 <https://doi.org/10.1001/jamanetworkopen.2021.43941>.
- 592 Monachino, A D, K L Lopez, L J Pierce, and L J Gabard-Durnam. 2022. “The HAPPE plus
593 Event-Related (HAPPE+ER) Software: A Standardized Preprocessing Pipeline for

- 594 Event-Related Potential Analyses.” *Modeling Neural Development* 57 (101140): 101140.
595 <https://doi.org/10.1016/j.dcn.2022.101140>.
- 596 Parker, Aimée, Sonia Fonseca, and Simon R. Carding. 2019. “Gut Microbes and Metabolites as
597 Modulators of Blood-Brain Barrier Integrity and Brain Health.” *Gut Microbes* 11 (2): 135–
598 57. <https://doi.org/10.1080/19490976.2019.1638722>.
- 599 Rhee, Sang H., Charalabos Pothoulakis, and Emeran A. Mayer. 2009. “Principles and Clinical
600 Implications of the Brain-Gut-Enteric Microbiota Axis.” *Nature Reviews*.
601 *Gastroenterology & Hepatology* 6 (5): 306–14. <https://doi.org/10.1038/nrgastro.2009.35>.
- 602 Subramanian, Aravind, Pablo Tamayo, Vamsi K. Mootha, Sayan Mukherjee, Benjamin L. Ebert,
603 Michael A. Gillette, Amanda Paulovich, et al. 2005. “Gene Set Enrichment Analysis: A
604 Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles.”
605 *Proceedings of the National Academy of Sciences* 102 (43): 15545–50.
606 <https://doi.org/10.1073/pnas.0506580102>.
- 607 Takesian, Anne E., Luke J. Bogart, Jeff W. Lichtman, and Takao K. Hensch. 2018. “Inhibitory
608 Circuit Gating of Auditory Critical-Period Plasticity.” *Nature Neuroscience* 21 (2): 218–27.
609 <https://doi.org/10.1038/s41593-017-0064-2>.
- 610 Tavares, Rejane G., Carla I. Tasca, Candice E. S. Santos, Moacir Wajner, Diogo O. Souza, and
611 Carlos S. Dutra-Filho. 2000. “Quinolinic Acid Inhibits Glutamate Uptake into Synaptic
612 Vesicles from Rat Brain.” *NeuroReport* 11 (2): 249.
- 613 Valles-Colomer, Mireia, Gwen Falony, Youssef Darzi, Etti F Tigchelaar, Jun Wang, Raul Y
614 Tito, Carmen Schiweck, et al. 2019. “The Neuroactive Potential of the Human Gut
615 Microbiota in Quality of Life and Depression.” *Nature Microbiology* 4 (4): 623–32.
616 <https://doi.org/10.1038/s41564-018-0337-x>.
- 617 Wymore Brand, Meghan, Michael J. Wannemuehler, Gregory J. Phillips, Alexandra Proctor,
618 Anne-Marie Overstreet, Albert E. Jergens, Roger P. Orcutt, and James G. Fox. 2015.
619 “The Altered Schaedler Flora: Continued Applications of a Defined Murine Microbial
620 Community.” *ILAR Journal* 56 (2): 169–78. <https://doi.org/10.1093/ilar/ilv012>.
- 621 Yassour, Moran, Tommi Vatanen, Heli Siljander, Anu-Maaria Hämäläinen, Taina Härkönen,
622 Samppa J Ryhänen, Eric A Franzosa, et al. 2016. “Natural History of the Infant Gut
623 Microbiome and Impact of Antibiotic Treatment on Bacterial Strain Diversity and
624 Stability.” *Science Translational Medicine* 8 (343): 343ra81.
625 <https://doi.org/10.1126/scitranslmed.aad0917>.
- 626 Zieff, Michal R, Marlie Miles, Emmie Mbale, Emma Eastman, Lorna Ginnell, Steven C R
627 Williams, Derek K Jones, et al. 2024. “Characterizing Developing Executive Functions in
628 the First 1000 Days in South Africa and Malawi: The Khula Study.” *Wellcome Open*
629 *Research* 9 (March):157. <https://doi.org/10.12688/wellcomeopenres.19638.1>.